NCT02398396View on ClinicalTrials.gov

Investigating Meningococcal Vaccines in Adults

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

June 13, 2019

Conditions
Meningococcal VaccinesMeningococcal InfectionsNeisseria MeningitidisFactor H-binding Protein, Neisseria Meningitidi
Interventions
BIOLOGICAL

4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics

4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02398396 - Investigating Meningococcal Vaccines in Adults | Biotech Hunter | Biotech Hunter